csDMARDs Could Add to TNF Inhibitors ' Benefits in SpA csDMARDs Could Add to TNF Inhibitors ' Benefits in SpA

EuroSpA Research Collaboration data hint at better retention and remission rates with csDMARD-TNFi cotherapy vs TNFi alone in spondyloarthritis.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news